18

1

Logo

Resistell

Société | Suisse

Onglets principaux

A propos de votre organisation

Resistell AG is a deep-tech start-up incorporated in 2018 in Basel region.
It is developing the world's fastest Antibiotic Susceptibility Test (AST) based
on analysis of nanoscale vibrations of living cells. The company has transformed
a cutting edge nanomotion technique from EPFL into a technology platform consisting of a hardware, software, algorithmics and big data in the cloud, for wide spectrum of applications in life science.

Resistell is a clinical stage company. The validation of Resistell’s AST is taking place in the University Hospital in Lausanne. The clinical data for first ~100 patients is available and it shows around 98% accuracy with the gold standard. The second multi-site study including 3 European hospitals will start in Q3 2022.

Resistell’s device, Phenotech is CE marked for research market and has CE IVD certification for three bacteria-antibiotic combinations. The company will initiate first sales of R&D devices in Q3-Q4 2022.

Resistell has a very strong cross functional team of 23 employees, BSL2 laboratory for AST testing (to be accredited according to ISO 17025 in Q4 2022/Q1 2023) and own device assembly facility. So far, we produced 23 devices, used in Muttenz  and CHUV and additional 17 are under assembly.

We are currently raising funds in series B for the commercialisation of technology for R&D market and for further development and clinical validation of the diagnostic product. We are searching for CHF 5M to complete our CHF 10M B round.

Réseau (0)

Il n'y a pas encore d'organisations dans le réseau.

Activité récente

Vous n'êtes pas connecté(e)

Un certain nombre de contenus vous sont cachés et vous ne bénéficiez pas des fonctionnalités de mises en relation.

Log in or register pour accéder à l’intégralité des contenus et fonctionnalités d’EuroQuity : l’inscription est rapide et gratuite !